Format
Sort by
Items per page

Send to

Choose Destination

Best matches for A. Dömling:

Search results

Items: 1 to 20 of 166

1.

Rapid approach to complex boronic acids.

Neochoritis CG, Shaabani S, Ahmadianmoghaddam M, Zarganes-Tzitzikas T, Gao L, Novotná M, Mitríková T, Romero AR, Irianti MI, Xu R, Olechno J, Ellson R, Helan V, Kossenjans M, Groves MR, Dömling A.

Sci Adv. 2019 Jul 5;5(7):eaaw4607. doi: 10.1126/sciadv.aaw4607. eCollection 2019 Jul.

2.

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Błaszkiewicz U, Pustuła M, Butera R, Dömling A, Holak TA.

Molecules. 2019 May 30;24(11). pii: E2071. doi: 10.3390/molecules24112071. Review.

3.

Spontaneous trans-Selective Transfer Hydrogenation of Apolar Boron-Boron Double Bonds.

Dömling M, Arrowsmith M, Schmidt U, Werner L, Castro AC, Jiménez-Halla JOC, Bertermann R, Müssig J, Prieschl D, Braunschweig H.

Angew Chem Int Ed Engl. 2019 May 7. doi: 10.1002/anie.201902656. [Epub ahead of print]

PMID:
31062910
4.

Studies on vascular response to full superantigens and superantigen derived peptides: Possible production of novel superantigen variants with less vasodilation effect for tolerable cancer immunotherapy.

Bashraheel SS, AlQahtani AD, Rashidi FB, Al-Sulaiti H, Domling A, Orie NN, Goda SK.

Biomed Pharmacother. 2019 Jul;115:108905. doi: 10.1016/j.biopha.2019.108905. Epub 2019 May 3.

5.

Diverse Isoquinoline Scaffolds by Ugi/Pomeranz-Fritsch and Ugi/Schlittler-Müller Reactions.

Wang Y, Patil P, Kurpiewska K, Kalinowska-Tluscik J, Dömling A.

Org Lett. 2019 May 17;21(10):3533-3537. doi: 10.1021/acs.orglett.9b00778. Epub 2019 Apr 29.

6.

Novel Compounds Targeting the RNA-Binding Protein HuR. Structure-Based Design, Synthesis, and Interaction Studies.

Della Volpe S, Nasti R, Queirolo M, Unver MY, Jumde VK, Dömling A, Vasile F, Potenza D, Ambrosio FA, Costa G, Alcaro S, Zucal C, Provenzani A, Di Giacomo M, Rossi D, Hirsch AKH, Collina S.

ACS Med Chem Lett. 2019 Jan 21;10(4):615-620. doi: 10.1021/acsmedchemlett.8b00600. eCollection 2019 Apr 11.

PMID:
30996806
7.

MCR Scaffolds Get Hotter with 18F-Labeling.

Zarganes-Tzitzikas T, Clemente GS, Elsinga PH, Dömling A.

Molecules. 2019 Apr 4;24(7). pii: E1327. doi: 10.3390/molecules24071327.

8.

Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.

Al-Qahtani AD, Bashraheel SS, Rashidi FB, O'Connor CD, Romero AR, Domling A, Goda SK.

Biomed Pharmacother. 2019 Apr;112:108725. doi: 10.1016/j.biopha.2019.108725. Epub 2019 Feb 28.

9.

Acoustic Droplet Ejection Enabled Automated Reaction Scouting.

Wang Y, Shaabani S, Ahmadianmoghaddam M, Gao L, Xu R, Kurpiewska K, Kalinowska-Tluscik J, Olechno J, Ellson R, Kossenjans M, Helan V, Groves M, Dömling A.

ACS Cent Sci. 2019 Mar 27;5(3):451-457. doi: 10.1021/acscentsci.8b00782. Epub 2019 Feb 27.

10.

Atorvastatin (Lipitor) by MCR.

Zarganes-Tzitzikas T, Neochoritis CG, Dömling A.

ACS Med Chem Lett. 2019 Feb 7;10(3):389-392. doi: 10.1021/acsmedchemlett.8b00579. eCollection 2019 Mar 14.

11.

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.

Neochoritis CG, Kazemi Miraki M, Abdelraheem EMM, Surmiak E, Zarganes-Tzitzikas T, Łabuzek B, Holak TA, Dömling A.

Beilstein J Org Chem. 2019 Feb 20;15:513-520. doi: 10.3762/bjoc.15.45. eCollection 2019.

12.

Stapled Peptides Inhibitors: A New Window for Target Drug Discovery.

Ali AM, Atmaj J, Van Oosterwijk N, Groves MR, Dömling A.

Comput Struct Biotechnol J. 2019 Feb 19;17:263-281. doi: 10.1016/j.csbj.2019.01.012. eCollection 2019. Review.

13.

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment.

AlQahtani AD, O'Connor D, Domling A, Goda SK.

Biomed Pharmacother. 2019 May;113:108750. doi: 10.1016/j.biopha.2019.108750. Epub 2019 Mar 5. Review.

14.

Oligomeric protein interference validates druggability of aspartate interconversion in Plasmodium falciparum.

Batista FA, Bosch SS, Butzloff S, Lunev S, Meissner KA, Linzke M, Romero AR, Wang C, Müller IB, Dömling ASS, Groves MR, Wrenger C.

Microbiologyopen. 2019 Feb 28:e779. doi: 10.1002/mbo3.779. [Epub ahead of print]

15.

A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Skalniak L, Twarda-Clapa A, Neochoritis CG, Surmiak E, Machula M, Wisniewska A, Labuzek B, Ali AM, Krzanik S, Dubin G, Groves M, Dömling A, Holak TA.

FEBS J. 2019 Apr;286(7):1360-1374. doi: 10.1111/febs.14774. Epub 2019 Feb 16.

PMID:
30715803
16.

Tetrazoles via Multicomponent Reactions.

Neochoritis CG, Zhao T, Dömling A.

Chem Rev. 2019 Feb 13;119(3):1970-2042. doi: 10.1021/acs.chemrev.8b00564. Epub 2019 Feb 1.

17.

Automated and Accelerated Synthesis of Indole Derivatives on a Nano-Scale.

Shaabani S, Xu R, Ahmadianmoghaddam M, Gao L, Stahorsky M, Olechno J, Ellson R, Kossenjans M, Helan V, Dömling A.

Green Chem. 2019 Jan 21;21(2):225-232. doi: 10.1039/C8GC03039A. Epub 2018 Dec 21.

PMID:
30686932
18.

Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.

Iordanidou D, Zarganes-Tzitzikas T, Neochoritis CG, Dömling A, Lykakis IN.

ACS Omega. 2018 Nov 30;3(11):16005-16013. doi: 10.1021/acsomega.8b02749. Epub 2018 Nov 27.

19.

Macrocycles: MCR synthesis and applications in drug discovery.

Abdelraheem EMM, Shaabani S, Dömling A.

Drug Discov Today Technol. 2018 Nov;29:11-17. doi: 10.1016/j.ddtec.2018.06.008. Epub 2018 Jul 12. Review.

PMID:
30471668
20.

The Catalytic Enantioselective Ugi Four-Component Reactions.

Shaabani S, Dömling A.

Angew Chem Int Ed Engl. 2018 Dec 10;57(50):16266-16268. doi: 10.1002/anie.201811129. Epub 2018 Nov 15. Review.

Supplemental Content

Loading ...
Support Center